These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 34162138)

  • 1. Recent development and optimization of pseudomonas aeruginosa exotoxin immunotoxins in cancer therapeutic applications.
    Wu T; Zhu J
    Int Immunopharmacol; 2021 Jul; 96():107759. PubMed ID: 34162138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer.
    Weldon JE; Pastan I
    FEBS J; 2011 Dec; 278(23):4683-700. PubMed ID: 21585657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New insights on
    Morgan RN; Saleh SE; Farrag HA; Aboshanab KM
    Ther Deliv; 2023 Jan; 14(1):31-60. PubMed ID: 36950853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of Immunotoxins Containing
    Mazor R; Pastan I
    Front Immunol; 2020; 11():1261. PubMed ID: 32695104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pseudomonas exotoxin and recombinant immunotoxins derived from it.
    Fitzgerald D; Pastan I
    Ann N Y Acad Sci; 1993 Jun; 685():740-5. PubMed ID: 8363279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Designing the furin-cleavable linker in recombinant immunotoxins based on Pseudomonas exotoxin A.
    Weldon JE; Skarzynski M; Therres JA; Ostovitz JR; Zhou H; Kreitman RJ; Pastan I
    Bioconjug Chem; 2015 Jun; 26(6):1120-8. PubMed ID: 25997032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trials with Pseudomonas exotoxin immunotoxins.
    Pai LH; Pastan I
    Curr Top Microbiol Immunol; 1998; 234():83-96. PubMed ID: 9670614
    [No Abstract]   [Full Text] [Related]  

  • 8. Recombinant immunotoxins for treating cancer.
    FitzGerald DJ; Kreitman R; Wilson W; Squires D; Pastan I
    Int J Med Microbiol; 2004 Apr; 293(7-8):577-82. PubMed ID: 15149034
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Leshem Y; Pastan I
    Toxins (Basel); 2019 Jan; 11(1):. PubMed ID: 30621280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL13 Fused
    Uludağ D; Karakaş N
    Anticancer Res; 2021 Jul; 41(7):3471-3480. PubMed ID: 34230142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotoxins in cancer therapy.
    Kreitman RJ
    Curr Opin Immunol; 1999 Oct; 11(5):570-8. PubMed ID: 10508704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxicity of chimeric (human-murine) monoclonal antibody BR96 IgG, F(ab')2, and Fab' conjugated to Pseudomonas exotoxin.
    Siegall CB; Gawlak SL; Chin JJ; Zoeckler ME; Kadow KF; Brown JP; Braslawsky GR
    Bioconjug Chem; 1992; 3(4):302-7. PubMed ID: 1390985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant heregulin-Pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo.
    Yang D; Kuan CT; Payne J; Kihara A; Murray A; Wang LM; Alimandi M; Pierce JH; Pastan I; Lippman ME
    Clin Cancer Res; 1998 Apr; 4(4):993-1004. PubMed ID: 9563895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-chain fusion toxins for the treatment of breast cancer: antitumor activity of BR96 sFv-PE40 and heregulin-PE40.
    Siegall CB
    Recent Results Cancer Res; 1996; 140():51-60. PubMed ID: 8787077
    [No Abstract]   [Full Text] [Related]  

  • 15. [Recombinant immunotoxins and chimeric toxins for targeted therapy in oncology].
    Chiron MF
    Bull Cancer; 1997 Dec; 84(12):1135-40. PubMed ID: 9587366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric fusion proteins--Pseudomonas exotoxin-based.
    Kreitman RJ
    Curr Opin Investig Drugs; 2001 Sep; 2(9):1282-93. PubMed ID: 11717817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant antibody fragments and immunotoxin fusions for cancer therapy.
    Brinkmann U
    In Vivo; 2000; 14(1):21-7. PubMed ID: 10757057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies.
    Kreitman RJ
    BioDrugs; 2009; 23(1):1-13. PubMed ID: 19344187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Protein engineering of Pseudomonas exotoxin and its targeting therapy of cancer].
    Kondo T
    Tanpakushitsu Kakusan Koso; 1989 Oct; 34(13):1793-803. PubMed ID: 2513619
    [No Abstract]   [Full Text] [Related]  

  • 20. Recombinant, ETA'-based CD64 immunotoxins: improved efficacy by increased valency, both in vitro and in vivo in a chronic cutaneous inflammation model in human CD64 transgenic mice.
    Ribbert T; Thepen T; Tur MK; Fischer R; Huhn M; Barth S
    Br J Dermatol; 2010 Aug; 163(2):279-86. PubMed ID: 20426788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.